Satapathy Sukanta, Patro Chandra Sekhar
Centurion University of Technology and Management, Odisha, India.
Adv Pharm Bull. 2022 Mar;12(2):298-308. doi: 10.34172/apb.2022.041. Epub 2021 Jul 3.
Tyrosine kinase inhibitors (TKIs) are used as targeted therapy for cancer by inhibiting the signaling pathway and tumor growth. Many TKIs got approved by FDA in recent times for the treatment of cancer by oral route. However, the TKIs have formulation challenges leading to compromised bioavailability which can cause a weak therapeutic response. The cancer nanotherapeutics using nanocarriers based drug delivery has emerged as an advanced tool to provide a solution to formulation challenges and a better cancer therapy by overcoming the limitations in conventional cancer therapy. This review describes the various formulation issues of anticancer drugs with a special reference to TKIs, as well as the capability of solid lipid nanoparticles (SLNs) for an efficient nano targeted cancer drug delivery.
酪氨酸激酶抑制剂（TKIs）通过抑制信号通路和肿瘤生长，被用作癌症的靶向治疗药物。近年来，许多TKIs经美国食品药品监督管理局（FDA）批准可通过口服途径用于癌症治疗。然而，TKIs存在制剂方面的挑战，导致生物利用度受损，进而可能引发较弱的治疗反应。基于纳米载体药物递送的癌症纳米疗法已成为一种先进工具，通过克服传统癌症治疗的局限性，为解决制剂挑战和实现更好的癌症治疗提供解决方案。本综述描述了抗癌药物的各种制剂问题，特别提及了TKIs，以及固体脂质纳米粒（SLNs）在高效纳米靶向癌症药物递送方面的能力。
